{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:27:31Z","timestamp":1760909251892},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Natural Science Foundation of Beijing","award":["NO. 7192053"],"award-info":[{"award-number":["NO. 7192053"]}]},{"name":"High Level Backbone Doctor Training Project of Beijing Health System","award":["NO. 2015-3-054"],"award-info":[{"award-number":["NO. 2015-3-054"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This prospective randomized comparative trial study aimed to evaluate the therapeutic outcomes of radical nephroureterectomy and adjuvant chemotherapy (ACT) used in combination in high risk upper tract urothelial carcinoma (UTUC) patients with cardiovascular comorbidity. Based on the inclusion criteria of high-risk UTUC in EAU guidelines (updated in 2014), all eligible patients treated in our hospital from January 2014 to March 2018 were included, and cases with late disease, renal dysfunction, severe cardiopulmonary disease or other malignant tumors were excluded. The cases were randomized into two groups based on treatment regimen. Multivariate analyses were performed to analyze the influencing factors of survival outcome in the enrolled patients. The Cox proportional-hazards model and the Kaplan\u2013Meier method were employed to assess progression free survival (PFS), overall survival (OS) and cancer specific survival (CSS). In addition, the potential adverse effects of chemotherapy were actively monitored. A total of 176 high-risk UTUC individuals with cardiovascular comorbidity were enrolled and evaluated in this study. Median follow-up durations were 30\u00a0months (range 6\u201354) in the RNU (n\u2009=\u200982) group and 36\u00a0months (range 6\u201354) in the RNU\u2009+\u2009ACT (n\u2009=\u200994) group. Multivariable analysis indicated that peri-operative cardiovascular events risk grade was independent prognostic factor for OS. Tumor size was independent prognostic factor for PFS and CSS. BMI and lymphovacular invasion were significant predictors of PFS. Clinical stage, lymph node involvement, and tumor grade were significant predictors of PFS, OS and CSS in these patients. Especially, chemotherapy was helpful in improving PFS [<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001, HR\u2009=\u20096.327 (5.115\u20137.793)], OS [<jats:italic>P<\/jats:italic>\u2009=\u20090.013, HR\u2009=\u20092.336 (1.956\u20132.883)] and CSS [<jats:italic>P<\/jats:italic>\u2009=\u20090.008, HR\u2009=\u20093.073 (2.533\u20133.738)]. Kaplan\u2013Meier analysis demonstrated that the oncologic outcomes of RNU treated high-risk UTUC patients were improved much significantly by ACT, including PFS [<jats:italic>P<\/jats:italic>\u2009=\u20090.0033, HR\u2009=\u20093.78 (3.13\u20134.55)], OS [<jats:italic>P<\/jats:italic>\u2009=\u20090.0397, HR\u2009=\u20091.39 (1.01\u20131.75)] and CSS [<jats:italic>P<\/jats:italic>\u2009=\u20090.0255, HR\u2009=\u20091.26 (1.07\u20131.45)]. Further analysis of the lymph node positive subgroup showed that the median time of oncologic events was enhanced in RNU\u2009+\u2009ACT treated individuals in comparison with the RNU group, including PFS (11.4\u00a0months vs. 31.9\u00a0months, <jats:italic>P<\/jats:italic>\u2009=\u20090.0018), OS (26.8\u00a0months vs. 36.3\u00a0months, <jats:italic>P<\/jats:italic>\u2009=\u20090.0255) and CSS (28.2\u00a0months vs. 39.3\u00a0months, <jats:italic>P<\/jats:italic>\u2009=\u20090.0197). In the T3\/4 cohort, significantly increased median PFS (13.9\u00a0months vs. 36.3\u00a0months, <jats:italic>P<\/jats:italic>\u2009=\u20090.0217), OS (20.6\u00a0months vs. 32.2\u00a0months, <jats:italic>P<\/jats:italic>\u2009=\u20090.0183) and CSS (21.9\u00a0months vs. 38.4\u00a0months, <jats:italic>P<\/jats:italic>\u2009=\u20090.0226) were obtained in the combination group. Additionally, no severe adverse events (over grade 4) associated with chemotherapy were detected in the RNU\u2009+\u2009ACT group. In conclusion, ACT after radical surgery has statistically significant therapeutic effects on PFS, OS and CSS in high-risk UTUC patients with cardiovascular comorbidity.<\/jats:p>","DOI":"10.1038\/s41598-020-74940-x","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T10:09:45Z","timestamp":1603102185000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Adjuvant chemotherapy after radical nephroureterectomy improves the survival outcome of high-risk upper tract urothelial carcinoma patients with cardiovascular comorbidity"],"prefix":"10.1038","volume":"10","author":[{"given":"Yong","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingfu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dechao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yili","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingchuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunhua","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongguang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,19]]},"reference":[{"key":"74940_CR1","doi-asserted-by":"publisher","first-page":"e000126","DOI":"10.1136\/esmoopen-2016-000126","volume":"1","author":"JJ Leow","year":"2017","unstructured":"Leow, J. J., Chong, K. T., Chang, S. L. & Bellmunt, J. Upper tract urothelial carcinoma: a different disease entity in terms of management. ESMO Open 1, e000126. https:\/\/doi.org\/10.1136\/esmoopen-2016-000126 (2017).","journal-title":"ESMO Open"},{"key":"74940_CR2","doi-asserted-by":"publisher","first-page":"101500","DOI":"10.18632\/oncotarget.21551","volume":"8","author":"Y Kubota","year":"2017","unstructured":"Kubota, Y. et al. Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study. Oncotarget 8, 101500\u2013101508. https:\/\/doi.org\/10.18632\/oncotarget.21551 (2017).","journal-title":"Oncotarget"},{"key":"74940_CR3","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s00345-016-1995-z","volume":"35","author":"A Aziz","year":"2017","unstructured":"Aziz, A. et al. Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review. World J. Urol. 35, 1401\u20131407. https:\/\/doi.org\/10.1007\/s00345-016-1995-z (2017).","journal-title":"World J. Urol."},{"key":"74940_CR4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11864-019-0637-2","volume":"20","author":"M Azizi","year":"2019","unstructured":"Azizi, M. et al. Optimal management of upper tract urothelial carcinoma: an unmet need. Curr. Treat. Options Oncol. 20, 40. https:\/\/doi.org\/10.1007\/s11864-019-0637-2 (2019).","journal-title":"Curr. Treat. Options Oncol."},{"key":"74940_CR5","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.juro.2009.05.011","volume":"182","author":"NJ Hellenthal","year":"2009","unstructured":"Hellenthal, N. J. et al. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J. Urol. 182, 900\u2013906. https:\/\/doi.org\/10.1016\/j.juro.2009.05.011 (2009).","journal-title":"J. Urol."},{"key":"74940_CR6","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/j.1442-2042.2008.02114.x","volume":"15","author":"N Soga","year":"2010","unstructured":"Soga, N., Arima, K. & Sugimura, Y. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma. Int. J. Urol. 15, 800\u2013803. https:\/\/doi.org\/10.1111\/j.1442-2042.2008.02114.x (2010).","journal-title":"Int. J. Urol."},{"key":"74940_CR7","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.urolonc.2016.11.018","volume":"35","author":"A Cohen","year":"2017","unstructured":"Cohen, A., Kuchta, K. & Park, S. Neoadjuvant and adjuvant chemotherapy use in upper tract urothelial carcinoma. Urol. Oncol. 35, 322\u2013327. https:\/\/doi.org\/10.1016\/j.urolonc.2016.11.018 (2017).","journal-title":"Urol. Oncol."},{"key":"74940_CR8","doi-asserted-by":"publisher","first-page":"686","DOI":"10.7150\/jca.7326","volume":"4","author":"TS Kim","year":"2013","unstructured":"Kim, T. S., Oh, J. H. & Rhew, H. Y. The efficacy of adjuvant chemotherapy for locally advanced upper tract urothelial cell carcinoma. J. Cancer 4, 686\u2013690. https:\/\/doi.org\/10.7150\/jca.7326 (2013).","journal-title":"J. Cancer"},{"key":"74940_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000092930","volume":"77","author":"SE Lee","year":"2006","unstructured":"Lee, S. E. et al. Adjuvant chemotherapy in the management of pT3N0M0 transitional cell carcinoma of the upper urinary tract. Urol. Int. 77, 22\u201326. https:\/\/doi.org\/10.1159\/000092930 (2006).","journal-title":"Urol. Int."},{"key":"74940_CR10","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bju.14020","volume":"121","author":"A Necchi","year":"2018","unstructured":"Necchi, A. et al. Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. BJU Int. 121, 252\u2013259. https:\/\/doi.org\/10.1111\/bju.14020 (2018).","journal-title":"BJU Int."},{"key":"74940_CR11","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1200\/JCO.2016.69.4141","volume":"35","author":"T Seisen","year":"2017","unstructured":"Seisen, T. et al. Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and\/or positive regional lymph node upper tract urothelial carcinoma. J. Clin. Oncol. 35, 852\u2013860. https:\/\/doi.org\/10.1200\/JCO.2016.69.4141 (2017).","journal-title":"J. Clin. Oncol."},{"key":"74940_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4111\/kju.2015.56.1.41","volume":"56","author":"KS Lee","year":"2015","unstructured":"Lee, K. S. et al. Impact of adjuvant chemotherapy in patients with upper tract urothelial carcinoma and lymphovascular invasion after radical nephroureterectomy. Korean J. Urol. 56, 41\u201347. https:\/\/doi.org\/10.4111\/kju.2015.56.1.41 (2015).","journal-title":"Korean J. Urol."},{"key":"74940_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.juro.2015.03.077","volume":"194","author":"YC Huang","year":"2015","unstructured":"Huang, Y. C. et al. The efficacy of postoperative adjuvant chemotherapy for patients with pT3N0M0 upper tract urothelial carcinoma. J. Urol. 194, 323\u2013329. https:\/\/doi.org\/10.1016\/j.juro.2015.03.077 (2015).","journal-title":"J. Urol."},{"key":"74940_CR14","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s00345-017-2032-6","volume":"35","author":"T Nakagawa","year":"2017","unstructured":"Nakagawa, T. et al. Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study. World J. Urol. 35, 1569\u20131575. https:\/\/doi.org\/10.1007\/s00345-017-2032-6 (2017).","journal-title":"World J. Urol."},{"issue":"6 Suppl","key":"74940_CR15","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1200\/JCO.2018.36.6_suppl.407","volume":"36","author":"AJ Birtle","year":"2018","unstructured":"Birtle, A. J., Chester, J. D. & Jones, R. J. M. Results of POUT: A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). J. Clin. Oncol. 36(6 Suppl), 407 (2018).","journal-title":"J. Clin. Oncol."},{"key":"74940_CR16","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.3760\/cma.j.issn.0376-2491.2018.32.008","volume":"98","author":"X Li","year":"2018","unstructured":"Li, X. et al. Impact of first-line chemotherapy on renal function in patients with advanced upper tract urothelial carcinoma. Zhonghua Yi Xue Za Zhi 98, 2574\u20132578. https:\/\/doi.org\/10.3760\/cma.j.issn.0376-2491.2018.32.008 (2018).","journal-title":"Zhonghua Yi Xue Za Zhi"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74940-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74940-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74940-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T21:54:28Z","timestamp":1670363668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74940-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,19]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["74940"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-74940-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,19]]},"assertion":[{"value":"24 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17674"}}